Cardiometabolic risk management: insights from a European Society of Cardiology Cardiovascular Round Table

Francesco Cosentino*, Subodh Verma, Philip Ambery, Marianne Bach Treppendahl, Martin Van Eickels, Stefan D. Anker, Michele Cecchini, Paola Fioretto, Per Henrik Groop, David Hess, Kamlesh Khunti, Carolyn S.P. Lam, Isabelle Richard-Lordereau, Lars H. Lund, Paul Mcgreavy, Philip N. Newsome, Naveed Sattar, Scott Solomon, Franz Weidinger, Faiez ZannadAndreas Zeiher

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Metabolic comorbidities are common in patients with cardiorenal disease; they can cause atherosclerotic cardiovascular disease (ASCVD), speed progression, and adversely affect prognosis. Common comorbidities are Type 2 diabetes mellitus (T2DM), obesity/overweight, chronic kidney disease (CKD), and chronic liver disease. The cardiovascular system, kidneys, and liver are linked to many of the same risk factors (e.g. dyslipidaemia, hypertension, tobacco use, diabetes, and central/truncal obesity), and shared metabolic and functional abnormalities lead to damage throughout these organs via overlapping pathophysiological pathways. The COVID-19 pandemic has further complicated the management of cardiometabolic diseases. Obesity, T2DM, CKD, and liver disease are associated with increased risk of poor outcomes of COVID-19 infection, and conversely, COVID-19 can lead to worsening of pre-existing ASCVD. The high rates of these comorbidities highlight the need to improve recognition and treatment of ASCVD in patients with obesity, insulin resistance or T2DM, chronic liver diseases, and CKD and equally, to improve recognition and treatment of these diseases in patients with ASCVD. Strategies to prevent and manage cardiometabolic diseases include lifestyle modification, pharmacotherapy, and surgery. There is a need for more programmes at the societal level to encourage a healthy diet and physical activity. Many pharmacotherapies offer mechanism-based approaches that can target multiple pathophysiological pathways across diseases. These include sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, selective mineralocorticoid receptor antagonists, and combined glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist. Non-surgical and surgical weight loss strategies can improve cardiometabolic disorders in individuals living with obesity. New biomarkers under investigation may help in the early identification of individuals at risk and reveal new treatment targets.

Original languageEnglish
Pages (from-to)4141-4156
Number of pages16
JournalEuropean Heart Journal
Volume44
Issue number39
Early online date14 Jul 2023
DOIs
Publication statusPublished - 14 Oct 2023

Bibliographical note

Funding Information:
This article was generated from discussions during a virtual Cardiovascular Round Table (CRT) workshop organized in May 2022 by the European Society of Cardiology (ESC). The ESC CRT is a strategic forum for high-level dialogue between 20 industry companies (pharmaceutical, devices, and diagnostics) and the ESC leadership to identify and discuss key strategic issues for the future of cardiovascular health in Europe. The authors alone are responsible for the views expressed in this manuscript, which do not necessarily represent the views or policies of the institution to which the authors are affiliated. The authors would like to thank Pauline Lavigne and Steven Portelance (unaffiliated, supported by the ESC) for contributions to writing and editing the manuscript.

Publisher Copyright:
© 2023 The Author(s).

Keywords

  • Atherosclerotic cardiovascular disease
  • Bariatric surgery
  • Cardiometabolic risk factors
  • Chronic kidney disease
  • Chronic liver diseases
  • COVID-19
  • Glucagon-like peptide-1 receptor agonists
  • Obesity
  • Sodium glucose cotransporter-2 inhibitors
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Cardiometabolic risk management: insights from a European Society of Cardiology Cardiovascular Round Table'. Together they form a unique fingerprint.

Cite this